Adenine

Adenine

SCHEMBL1408058

NC(=O)c1cccnc1.Nc1ncnc2[nH]cnc12.O=P(O)(O)O

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

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

The experimentally established mechanism targets of Adenine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR known ✓ P35968 1/20 0.44
▸ F7 P08709 1/20 0.51
▸ F3 P13726 1/20 0.51
▸ SARM1 Q6SZW1 1/20 0.51
▸ SIRT2 Q8IXJ6 1/20 0.51
▸ SIRT6 Q8N6T7 1/20 0.51
▸ SIRT1 Q96EB6 1/20 0.51
▸ SIRT3 Q9NTG7 1/20 0.51
▸ SIRT5 Q9NXA8 1/20 0.51
▸ SIRT4 Q9Y6E7 1/20 0.51
▸ EGFR P00533 1/20 0.44
▸ SRC P12931 1/20 0.44
▸ HDAC1 Q13547 2/20 0.40
▸ HDAC6 Q9UBN7 1/20 0.40
▸ HDAC3 O15379 1/20 0.39
▸ HDAC2 Q92769 1/20 0.39
▸ CCNA2 P20248 1/20 0.39
▸ CDK2 P24941 1/20 0.39
▸ ATR Q13535 2/20 0.39
▸ LMNA P02545 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Adenine SCHEMBL19057040 1.00 F7 (0.51) F7F3SARM1SIRT2SIRT6
Adenine SCHEMBL15699 0.95 F7 (0.56) F7F3SARM1SIRT2SIRT6
Adenine SCHEMBL22748483 0.95 F7 (0.56) F7F3SARM1SIRT2SIRT6
Adenine SCHEMBL2564207 0.95 F7 (0.56) F7F3SARM1SIRT2SIRT6
Adenine SCHEMBL23859925 0.94 F7 (0.55) F7F3SARM1SIRT2SIRT6
Adenine SCHEMBL7712105 0.94 F7 (0.55) F7F3SARM1SIRT2SIRT6
Adenine SCHEMBL22129922 0.94 F7 (0.55) F7F3SARM1SIRT2SIRT6
Adenine SCHEMBL28614873 0.94 F7 (0.55) F7F3SARM1SIRT2SIRT6
Adenine SCHEMBL23531099 0.94 F7 (0.55) F7F3SARM1SIRT2SIRT6
Adenine SCHEMBL11807677 0.94 F7 (0.55) F7F3SARM1SIRT2SIRT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1337625-B1 STEM CELLS, METHOD FOR EXPANSION IN VITRO AND USE THEREOF SCHELLER ALBERT (DE) 2004-07-14 — — EP claimed
US-6642031-B2 Pseudomonas microorganism for use in the generation of indigo GENENCOR INTERNATIONAL, INC. 2003-11-04 — — US claimed
JP-8231404-A — — None — — JP disclosed
WO-2023143356-A1 METHIONINE ADENOSYLTRANSFERASE 2A INHIBITOR FOR TREATING MTAP DELETION-TYPE CANCER 勤浩医药(苏州)有限公司 2023-08-03 — — WO disclosed
US-11629340-B2 DHFR tunable protein regulation OBSIDIAN THERAPEUTICS, INC. (US) 2023-04-18 — — US disclosed
US-20230092895-A1 TANDEM CD19 CAR-BASED COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY OBSIDIAN THERAPEUTICS, INC. 2023-03-23 — — US disclosed
US-20230089537-A1 DIETARY SUPPLEMENT AND METHOD FOR SYNTHESIS OF SAME StrongCell LLC 2023-03-23 — — US disclosed
US-20230091651-A1 DIETARY SUPPLEMENT AND METHOD FOR SYNTHESIS OF SAME StrongCell LLC 2023-03-23 — — US disclosed
US-20220213449-A1 DHFR TUNABLE PROTEIN REGULATION OBSIDIAN THERAPEUTICS, INC. (US) 2022-07-07 — — US disclosed
US-20220175781-A1 CD40L COMPOSITIONS AND METHODS FOR TUNABLE REGULATION OBSIDIAN THERAPEUTICS, INC. (US) 2022-06-09 — — US disclosed
CN-114480563-A Composition and kit for detecting adenosine deaminase activity 广州达安基因股份有限公司 2022-05-13 — — CN disclosed
EP-0932662-A1 MICROORGANISMS WITH ABILITY TO DEGRADE INDOLE AND ENZYMES THEREFROM GENENCOR INTERNATIONAL, INC. (US) 1999-08-04 — — EP disclosed
EP-0872244-A1 Cosmetic or pharmaceutical composition containing an Andiroba extract LABORATOIRES DE BIOLOGIE VEGETALE YVES ROCHER (FR) 1998-10-21 — — EP disclosed
US-5750512-A FOR TREATMENT OF PARKINSON'S AND ALZHEIMER'S DISEASE OR MENTAL DEPRESSION BIRKMAYER PHARMACEUTICALS, INC. (US) 1998-05-12 — — US disclosed
WO-1998013474-A1 MICROORGANISMS WITH ABILITY TO DEGRADE INDOLE AND ENZYMES THEREFROM GENENCOR INTERNATIONAL, INC. (US) 1998-04-02 — — WO disclosed
US-5654288-A OXIDATION RESISTANCE BIRKMAYER PHARMACEUTICALS, INC. (US) 1997-08-05 — — US disclosed
JP-H08231404-A NADH AND NADPH THERAPEUTIC AGENT FOR NASAL, SUBLINGUAL, RECTAL AND DERMAL ADMINISTRATION BIRKMAYER USA 1996-09-10 — — JP disclosed
EP-0722734-A1 NADH and NADPH therapeutic agents for nasal, sublingual, rectal and dermal administration BIRKMAYER U.S.A. (US) 1996-07-24 — — EP disclosed
US-5508179-A INCUBATING MIXTURE OF NAD, NUCLEIC ACID OLIGONUCLEOTIDES AND A NAH DINUCLEOTIDE-DEPENDENT NUCLEIC ACID LIGASE; BIO-RAD LABORATORIES, INC. (US) 1996-04-16 — — US disclosed
US-5019561-A Treatment of Parkinson's disease with NADPH BIRKMAYER JOERG (AT) 1991-05-28 — — US disclosed
Send feedback